Humana Inc (HUM) Shares Sold by Argent Trust Co

Argent Trust Co decreased its position in Humana Inc (NYSE:HUM) by 0.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,599 shares of the insurance provider’s stock after selling 14 shares during the period. Argent Trust Co’s holdings in Humana were worth $330,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. APG Asset Management N.V. boosted its stake in shares of Humana by 6.0% in the third quarter. APG Asset Management N.V. now owns 194,678 shares of the insurance provider’s stock valued at $34,437,000 after buying an additional 11,100 shares during the last quarter. Thrivent Financial for Lutherans raised its position in Humana by 6.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 6,065 shares of the insurance provider’s stock valued at $1,235,000 after buying an additional 360 shares during the period. Baldwin Brothers Inc. MA raised its position in Humana by 2.7% in the first quarter. Baldwin Brothers Inc. MA now owns 67,441 shares of the insurance provider’s stock valued at $13,902,000 after buying an additional 1,782 shares during the period. A.R.T. Advisors LLC acquired a new position in Humana during the fourth quarter valued at approximately $3,427,000. Finally, Advantus Capital Management Inc raised its position in Humana by 1.0% in the third quarter. Advantus Capital Management Inc now owns 14,832 shares of the insurance provider’s stock valued at $2,624,000 after buying an additional 145 shares during the period. Institutional investors own 93.00% of the company’s stock.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Shares of Humana Inc (NYSE:HUM) traded down 0.40% during midday trading on Friday, reaching $227.89. 1,356,560 shares of the company were exchanged. Humana Inc has a 52-week low of $150.00 and a 52-week high of $233.66. The company’s 50-day moving average price is $219.16 and its 200 day moving average price is $207.26. The stock has a market capitalization of $32.89 billion, a price-to-earnings ratio of 23.23 and a beta of 0.91.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, May 3rd. The insurance provider reported $2.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.55 by $0.20. The business had revenue of $13.76 billion during the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 1.09% and a return on equity of 13.09%. During the same quarter in the prior year, the firm earned $1.86 EPS. On average, equities analysts predict that Humana Inc will post $11.14 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, July 31st. Investors of record on Friday, June 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, June 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.70%. Humana’s dividend payout ratio (DPR) is presently 29.59%.

TRADEMARK VIOLATION WARNING: This article was first posted by Mideast Time and is owned by of Mideast Time. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.mideasttime.com/humana-inc-hum-shares-sold-by-argent-trust-co/1708215.html.

Several equities analysts recently commented on HUM shares. Jefferies Group LLC reissued a “buy” rating and issued a $237.00 target price on shares of Humana in a report on Friday, March 24th. Deutsche Bank AG started coverage on Humana in a report on Wednesday, April 5th. They issued a “hold” rating and a $216.00 target price on the stock. Bank of America Corp started coverage on Humana in a report on Friday, January 27th. They issued a “buy” rating on the stock. Evercore ISI reissued an “overweight” rating on shares of Humana in a report on Monday, February 27th. Finally, Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $237.00 target price on the stock in a report on Tuesday, April 18th. Nine analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $216.12.

In related news, SVP Brian P. Leclaire sold 26,894 shares of the company’s stock in a transaction that occurred on Wednesday, February 22nd. The shares were sold at an average price of $205.24, for a total value of $5,519,724.56. Following the completion of the sale, the senior vice president now owns 25,734 shares in the company, valued at approximately $5,281,646.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO James E. Murray sold 70,332 shares of the company’s stock in a transaction that occurred on Tuesday, February 21st. The shares were sold at an average price of $205.20, for a total transaction of $14,432,126.40. Following the completion of the sale, the chief operating officer now owns 76,798 shares of the company’s stock, valued at approximately $15,758,949.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 456,402 shares of company stock valued at $96,803,127. 0.50% of the stock is owned by insiders.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

5 Day Chart for NYSE:HUM

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.